SEARCH

SEARCH BY CITATION

References

  • 1
    Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 1999; 341: 34252.
  • 2
    Singer S, Demetri GD, Baldini EH, Fletcher CD. Management of soft-tissue sarcomas: an overview and update. Lancet Oncol 2000; 1: 7585.
  • 3
    Meyers PA, Schwartz CL, Krailo M et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005; 23: 200411.
  • 4
    Ferrari S, Smeland S, Mercuri M et al. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 2005; 23: 884552.
  • 5
    Marcove RC. A clinical trial of autogenous vaccines in the treatment of osteogenic sarcoma. Beitr Pathol 1974; 153: 6572.
  • 6
    Neff JR, Enneking WF. Adoptive immunotherapy in primary osteosarcoma. An interim report. J Bone Joint Surg Am 1975; 57: 1458.
  • 7
    Geiger J, Hutchinson R, Hohenkirk L, McKenna E, Chang A, Mule J. Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells. Lancet 2000; 356: 11635.
  • 8
    Dagher R, Long LM, Read EJ et al. Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Med Pediatr Oncol 2002; 38: 15864.
  • 9
    Dillman R, Barth N, Selvan S et al. Phase I/II trial of autologous tumor cell line-derived vaccines for recurrent or metastatic sarcomas. Cancer Biother Radiopharm 2004; 19: 5818.
  • 10
    Kawaguchi S, Wada T, Ida K et al. Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma. J Transl Med 2005; 3: 1.
  • 11
    Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74: 181273.
  • 12
    Algarra I, Garcia-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother 2004; 53: 90410.
  • 13
    Bubenik J. MHC class I down-regulation: tumour escape from immune surveillance? Int J Oncol 2004; 25: 48791.
  • 14
    Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol 1999; 154: 74554.
  • 15
    Kamarashev J, Ferrone S, Seifert B et al. TAP1 down-regulation in primary melanoma lesions: an independent marker of poor prognosis. Int J Cancer 2001; 95: 238.
  • 16
    Hofbauer GF, Burkhart A, Schuler G, Dummer R, Burg G, Nestle FO. High frequency of melanoma-associated antigen or HLA class I loss does not correlate with survival in primary melanoma. J Immunother 2004; 27: 738.
  • 17
    Al-Batran SE, Rafiyan MR, Atmaca A et al. Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma. Cancer Res 2005; 65: 393741.
  • 18
    Cabrera T, Angustias Fernandez M, Sierra A et al. High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Hum Immunol 1996; 50: 12734.
  • 19
    Redondo M, Garcia J, Villar E et al. Major histocompatibility complex status in breast carcinogenesis and relationship to apoptosis. Hum Pathol 2003; 34: 12839.
  • 20
    Gobbi G, Mirandola P, Micheloni C et al. Expression of HLA class I antigen and proteasome subunits LMP-2 and LMP-10 in primary vs metastatic breast carcinoma lesions. Int J Oncol 2004; 25: 16259.
  • 21
    Madjd Z, Spendlove I, Pinder SE, Ellis IO, Durrant LG. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer 2005; 117: 24855.
  • 22
    Kageshita T, Ishihara T, Campoli M, Ferrone S. Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions. Tissue Antigens 2005; 65: 41928.
  • 23
    Korkolopoulou P, Kaklamanis L, Pezzella F, Harris AL, Gatter KC. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br J Cancer 1996; 73: 14853.
  • 24
    Ramnath N, Tan D, Li Q et al. Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival? Cancer Immunol Immunother 2005; 55: 89199.
  • 25
    Ferron A, Perez-Ayala M, Concha A et al. MHC class I and II antigens on gastric carcinomas and autologous mucosa. J Immunogenet 1989; 16: 41323.
  • 26
    Gutierrez J, Lopez-Nevot MA, Cabrera T et al. Class I and II HLA antigen distribution in normal mucosa, adenoma and colon carcinoma: relation with malignancy and invasiveness. Exp Clin Immunogenet 1987; 4: 14452.
  • 27
    Cabrera T, Collado A, Fernandez MA et al. High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas. Tissue Antigens 1998; 52: 11423.
  • 28
    Watson NF, Ramage JM, Madjd Z et al. Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer 2006; 118: 610.
  • 29
    Romero JM, Jimenez P, Cabrera T et al. Coordinated downregulation of the antigen presentation machinery and HLA class I/β2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer. Int J Cancer 2005; 113: 60510.
  • 30
    Vitale M, Pelusi G, Taroni B et al. HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. Clin Cancer Res 2005; 11: 6772.
  • 31
    Mechtersheimer G, Staudter M, Majdic O, Dorken B, Moldenhauer G, Moller P. Expression of HLA-A,B,C, β2-microglobulin (β2m), HLA-DR-DP-DQ and of HLA-D-associated invariant chain (Ii) in soft-tissue tumors. Int J Cancer 1990; 46: 81323.
  • 32
    Fernandez JE, Concha A, Aranega A, Ruiz-Cabello F, Cabrera T, Garrido F. HLA class I and II expression in rhabdomyosarcomas. Immunobiology 1991; 182: 4408.
  • 33
    Kaya M, Wada T, Akatsuka T et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 2000; 6: 5727.
  • 34
    Liu K, Kao KJ. Measurement of relative quantities of different HLA-A and -B mRNAs in cells by reverse transcription–polymerase chain reaction and denaturing gradient gel electrophoresis. J Immunol Meth 1997; 203: 6775.
  • 35
    Wada T, Isu K, Takeda N, Usui M, Ishii S, Yamawaki S. A preliminary report of neoadjuvant chemotherapy NSH-7 study in osteosarcoma: preoperative salvage chemotherapy based on clinical tumor response and the use of granulocyte colony-stimulating factor. Oncology 1996; 53: 2217.
  • 36
    Kawaguchi S, Wada T, Nagoya S et al. Extraskeletal myxoid chondrosarcoma: a multi-institutional study of 42 cases in Japan. Cancer 2003; 97: 128592.
  • 37
    Tsukahara T, Nabeta Y, Kawaguchi S et al. Identification of human autologous cytotoxic T-lymphocyte-defined osteosarcoma gene that encodes a transcriptional regulator, papillomavirus binding factor. Cancer Res 2004; 64: 54428.
  • 38
    Stam NJ, Spits H, Ploegh HL. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 1986; 137: 2299306.
  • 39
    Stam NJ, Vroom TM, Peters PJ, Pastoors EB, Ploegh HL. HLA-A- and HLA-B-specific monoclonal antibodies reactive with free heavy chains in western blots, in formalin-fixed, paraffin-embedded tissue sections and in cryo-immuno-electron microscopy. Int Immunol 1990; 2: 11325.
  • 40
    Chang CC, Campoli M, Ferrone S. HLA class I defects in malignant lesions: what have we learned? Keio J Med 2003; 52: 2209.
  • 41
    Hicklin DJ, Wang Z, Arienti F, Rivoltini L, Parmiani G, Ferrone S. β2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J Clin Invest 1998; 101: 27209.
  • 42
    Trieb K, Lechleitner T, Lang S, Windhager R, Kotz R, Dirnhofer S. Evaluation of HLA-DR expression and T-lymphocyte infiltration in osteosarcoma. Pathol Res Pract 1998; 194: 67984.